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Abstract
Synovial sarcoma (SS) is the most frequent nonrhabdomyosarcomatous soft tissue sarcoma encountered in ado-
lescents and young adults, and despite advances in the treatment of local disease, metastases remain the main
cause of death. The aim of this study was to characterize a single-center series of pediatric SS molecularly to seek
any biomarkers or pathways that might make suitable targets for new agents. Seventeen cases of pediatric SS
showing the SYT–SSX fusion transcript were screened immunohistochemically, biochemically, molecularly, and
cytogenetically (depending on the available material) to investigate any expression/activation of epidermal growth
factor receptor, platelet-derived growth factor receptor alpha (PDGFRα), PDGFRβ, Akt, and deregulated Wnt path-
way. The most relevant outcome was the finding of activated epidermal growth factor receptor, PDGFRα, and
PDGFRβ, which activated Akt in both the monophasic and biphasic histologic subtypes. Consistently, Akt activa-
tion was completely abolished in an SS cell line assay when stimulated by PDGF-AA and treated with the phos-
phatidylinositol 3-kinase inhibitor LY294002. Our results also showed the nuclear localization of β-catenin and
cyclin D1 gene products in monophasic SS and the movement of β-catenin into the cytoplasm in the glandular
component of the biphasic subtype. Although they need to be confirmed in larger series, these preliminary data
suggest that therapeutic strategies including specific inhibitors of the phosphatidylinositol 3-kinase/Akt pathway
might be exploited in SS.
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Introduction
Synovial sarcoma (SS) is one of the most common mesenchymal
malignancies and accounts for approximately 8% to 10% of all soft
tissue sarcomas; it is also reported to be the most frequent nonrhabdo-
myosarcomatous soft tissue sarcoma encountered in adolescents and
young adults (15–20% of cases). It is characterized by the specific
chromosomal translocation t(X;18) (p11;q11) that fuses the SYT gene
from chromosome 18 with the SSX1 (approximately 2/3 of cases),
SSX2 (approximately 1/3 of cases), or SSX4 gene (rare cases) from
the X chromosome. Although it is thought that SYT–SSX plays a cen-
tral part in the development of SS, the mechanism of tumor initiation
is still unknown.
Gene array and immunohistochemistry (IHC) studies have recently
identified high epidermal growth factor receptor (EGFR), Her-2/neu,
IGF2 and HGFR gene expression in SS [1,2], but the correlation be-
tween this and the activation of specific cascades [such as phosphati-
dylinositol 3-kinase (PI3K)/Akt] has not been fully investigated.
Akt is an intracellular serine/threonine kinase, which, once activated
by PI3K, moves from the cell membrane to the cytoplasm and/or
nucleus, where it controls survival (by inhibiting pro- and activating
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antiapoptotic factors), proliferation (by means of direct p21 and p27
phosphorylation), and other activities essential to tumor progression,
such as angiogenesis, invasion, and metastasis. It is a key activator of
the mammalian target of rapamycin that induces the expression of pro-
angiogenic genes by stabilizing the hypoxia-inducible factor. In addition
to direct GSK3B inactivation, it has also been shown that Akt directly
phosphorylates the β-catenin Ser 552 residue in epithelial cancer cells [3]
leading to the nuclear shift/activation of β-catenin.
In cell adhesion and transcription functions, β-catenin has the ap-
propriate selection of which is crucial for normal development and the
avoidance of cancer. It is well known that there is a striking cytoplasmic
and nuclear accumulation of β-catenin in most SS, which is consistent
with the recently reported presence of a transcriptionally active nuclear
complex containing SYT–SSX2 and β-catenin [4] and supports the
idea that the sarcoma chimeric protein contributes to cancer formation
by activating one of the β-catenin–targeted programs. However, be-
cause the accumulation of β-catenin in SS does not apparently depend
on canonical Wnt activation and mutations in APC, β-catenin, and
E-cadherin are rare [5,6], it may be that β-catenin is stabilized through
its phosphorylation by receptor tyrosine kinases (RTKs) [7].
Bearing this in mind, after making a preliminary immunopheno-
typic analysis, we investigated 17 cases of pediatric SS—all with an
SYT–SSX fusion transcript—using molecular biochemical methods
suited to the type of material available (formalin-fixed or frozen) to
seek any potential biomarkers or pathways that might be suitable
targets for licensed drugs, such as the expression of EGFR, platelet-
derived growth factor receptor alpha (PDGFRα), PDGFRβ, Akt,
and deregulated Wnt pathways.
Our findings support the expression and activation of EGFR,
PDGFRα, and PDGFRβ, which may activate Akt. These albeit pre-
liminary data suggest that therapeutic strategies including specific in-
hibitors of the PI3K/Akt pathway might be exploited in SS.
Materials and Methods
Patients and Materials
We analyzed specimens from 17 patients with SS (nine males and
eight females aged 7–18 years; median age, 11 years), all but one
of whom (BSS8 in Table 1) were treated at the Pediatric Oncology
Unit of the Fondazione IRCCS, Istituto Nazionale Tumori, Milan,
Italy. All of the specimens came from primary tumors and had
been obtained before any treatment had been given, and representative
samples obtained from formalin-fixed material were immunophe-
notyped. All of the biochemical and molecular analyses were made
using frozen sections after the tumoral component had been carefully
dissected under a microscope to avoid contamination by normal or ne-
crotic tissue.
Written informed consent was obtained from all of the patients
and/or their parents or legal guardians.
Immunohistochemistry
The samples were immunophenotyped using the following anti-
bodies and dilutions: PDGFRα (C-20), sc-338 rabbit polyclonal IgG
(Santa Cruz Biotechnology Inc., Santa Cruz, CA) diluted 1:200;
PDGFRβ (P-20), sc-339 rabbit polyclonal IgG (Santa Cruz Biotech-
nology) diluted 1:100; KIT, rabbit polyclonal antihuman CD117
(code A 4502; Dako, Carpinteria, CA) diluted 1:50; HER2/NEU,
c-erb-2 rabbit polyclonal antihuman Oncoprotein (code A 0485;
Dako) diluted 1:2000; cyclin D1 rabbit monoclonal antibody clone
SP4 (code RM-9104-S1; Lab Vision, Fremont, CA) diluted 1:100;
β-catenin mouse monoclonal antibody (clone 14, code C19220;
Transduction Laboratories, Lexington, KY) diluted 1:2000.
The antigens for all antibodies were retrieved using 5 mM citrate
buffer (pH 6) in an autoclave at 95°C for 6 minutes, except for cyclin
D1 and β-catenin, which took 30 minutes. All of these antibodies
were developed as described elsewhere [8].
Epidermal growth factor receptor was immunostained using the
EGFR-pharmDx kit (code K1492; Dako) following the manufac-
turer’s instructions. The EGFR-immunostained cells were quantita-
tively evaluated, and their staining intensity was scored as described
elsewhere [9]. The following positive controls were used in each IHC
experiment: one case of fibromatosis for PDGFRα and PDGFRβ,
one case of KIT-mutated GIST for KIT, one case of ductal salivary
gland carcinoma for HER2/NEU, one case of colon carcinoma for
β-catenin, and one case of mantle cell lymphoma for BCL1.
Table 1. Clinical Characteristic of Pediatric SS Patients.
Age (years) Site Stage Therapy Relapse Status
MSS1 17 Lower extremity T2 B N0 M0 S + CT + RXT 74 months DOD (106 months)
MSS2 7 Lower extremity T2 B N0 M0 S + CT + RXT 68 months DOD (120 months)
MSS3 16 Lower extremity T2 B N0 M0 S + CT + RXT 32 months PRO (150 months)
MSS4 17 Lower extremity T1 B N0 M0 S + CT + RXT No First CR (140 months)
MSS5 17 Pleura T2 B N0 M0 S + CT + RXT 9 months DOD (14 months)
MSS6 11 Upper extremity T1 A N0 M0 S + CT + RXT No First CR (102 months)
MSS7 10 Lower extremity T2 B N0 M0 S + CT + RXT 50 months DOD (58 months)
MSS8 15 Lower extremity T2 A N0 M0 S + CT + RXT No First CR (140 months)
BSS1 15 Lung T2 B N0 M0 S + CT + RXT 18 months DOD (50 months)
BSS2 10 Upper extremity T1 A N0 M0 S + CT No First CR (88 months)
BSS3 18 Head/neck T2 B N0 M0 S + CT + RXT No First CR (62 months)
BSS4 10 Lower extremity T2 B N0 M0 S + CT + RXT 56 months Third CR (170 months)
BSS5 15 Lower extremity T2 B N0 M0 S + CT 8 months DOD (72 months)
BSS6 12 Abdominal wall T2 B N0 M0 S + CT No First CR (125 months)
BSS7 15 Lower extremity T2 B N0 M0 S + CT + RXT No First CR (36 months)
BSS8 14 Lower extremity NA NA NA NA
BSS9 12 Lower extremity T2 A N0 M0 S + CT + RXT No First CR (200 months)
TNM classification based on local invasiveness, T1 and T2, and tumor size, A or B, i.e., less or more than 5 cm; absence or presence of nodal and distant involvement: N0 and N1, M0 and M1,
respectively [Harmer MH (1982). TNM Classification of Pediatric Tumors. UICC International Union Against Cancer, Geneva, Switzerland. pp. 23–28].
CR indicates complete remission; CT, chemotherapy; DOD, dead of disease; NA, not available; PRO, progressive disease; RXT, radiotherapy; S , surgery.
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Biochemical Analysis
Protein extraction and immunoprecipitation/Western blot anal-
ysis. The EGFR, PDGFRα, and PDGFRβ proteins were extracted,
immunoprecipitated, and blotted as described elsewhere [8]. The
A431 cell line (American Type Culture Collection, Manassas, VA)
was used as a positive control for the EGFR protein expression/
phosphorylation experiments, and the NIH3T3 cell line (Ameri-
can Type Culture Collection) for the PDGFRα protein expression/
phosphorylation experiments.
Twenty micrograms of cytoplasmic total protein extract was used
with anti–phospho-Akt Ser 473 polyclonal antibody (#9271; Cell
Signaling Technology, Beverly, MA) diluted 1:1000 in the Akt West-
ern blot (WB) experiments, and the filters were subsequently stripped
and incubated with anti-Akt polyclonal antibody (#9272; Cell Sig-
naling) diluted 1:1000; the NIH3T3 cell line was used as a positive
control. Thirty micrograms cytoplasmic total protein extract was
used with the anti–phospho-β-catenin Y142 (clone ab27798; Abcam,
Cambridge, UK) diluted 1:1000 in the β-catenin WB experiments,
and the filters were subsequently stripped and incubated with anti–-
β-catenin (clone BDI109; Abcam) diluted 1:1000; the A431 cell line
was used as a positive control.
CME-1 Cell Line Culture Conditions
The CME-1 cell line was cultured as previously described [10].
For the biochemical analyses, the CME-1 cells were serum-starved
for 16 hours, and then stimulated with 50 ng/ml of PDGF-AA (cat-
alogue 100-13A; PeproTech, Princeton, NJ) for 5, 15, 30, and 60 min-
utes. The PI3K inhibitor LY294002 (kindly provided by Dr. L. Lanzi,
Experimental Oncology Unit, Fondazione IRCCS, Istituto Nazionale
Tumori, Milan, Italy) was used at volumes of 0.5, 5, and 50 μM in
CME-1 serum-starved cells stimulated with 50 ng/ml of PDGF-AA
for 15 minutes.
The WB analyses were made as described above for the pri-
mary specimens.
RNA Extraction, Reverse Transcription, and cDNA Synthesis
Total RNAwas extracted from formalin-fixed materials and reverse-
transcribed. All of the samples were tested for cDNA integrity and
DNA contamination by amplifying the β-actin and HPRT (hypoxan-
thine guanine phosphoribosyl transferase) housekeeping genes.
Detection of Fusion Transcripts by Polymerase Chain Reaction
and Fluorescence In Situ Hybridization
SYT/SSX fusion transcripts were detected by polymerase chain re-
action (PCR) as described in detail elsewhere [11]. Briefly, good-
quality RNA was obtained from all 17 samples, all of which showed
the SYT–SSX gene fusion transcript: 11 (65%: 5/8 monophasic cases
and 6/9 biphasic cases) carried SYT–SSX1 and six (35%: 3/8 mono-
phasic and 3/9 biphasic cases) carried SYT–SSX2 (Table 2).
In all cases, the presence of an SYT–SSX translocation was con-
firmed by fluorescence in situ hybridization (FISH) analysis using
BAC probes RP11-38O23 and RP11-344N17 for SSX1, RP11-
552J9 and RP13-77O11 for SSX2, and RP11-737G21, RP11-
786F14, and RP11-399L5 for SYT as previously described [12].
EGFR and PDGFRα FISH Analyses
These were made using previously described probes [8].
Relative Quantification of RTK Receptor and
Ligand Expression
Epidermal growth factor receptor, PDGFRα, PDGFRβ, PDGFA,
TGFA, and glyceraldehyde-3-phosphate dehydrogenase cDNAs were
relatively quantified by means of real-time quantitative PCR (ABI
PRISM 5700 PCR Sequence Detection Systems; Applied Biosystems,
Foster City, CA) using a TaqMan-based analysis and following the
Table 2. Immunostaining Results of Pediatric SS Patients.
Syt/ssx β-Catenin BCL1 EGFR HER2/NEU PDGFRα PDGFRβ KIT
MSS1 2 ++N +N 4 + 3 high − +/− + −
MSS2 1 ++N +N 3 + 3 high − ++ + −
MSS3 2 ++N +N 3 + 2 high − ++ +/− −
MSS4 1 ++N +N 2 + 2 − ++ + −
MSS5 2 ++N/C +N 2 + 2 − ++ + −
MSS6 1 ++N/C +N 4 + 3 high − ++ +/− −
MSS7 1 ++C +N 4 + 3 high − +/− + −
MSS8 1 +C/N +N 2 + 2 − + + −
BSS1 1 Gland comp. + C/M ++N — − ++ +/− −
Spindle comp. — — High − ++ +/− −
BSS2 1 Gland comp. + C/M ++N — − ++ +/− +/−
Spindle comp. — — High − ++ +/− −
BSS3 1 Gland comp. + C/M ++N — − ++ +/− +/−
Spindle comp. — — High − ++ +/− −
BSS4 1 Gland comp. + C/M ++N — +/− ++ + +/−
Spindle comp. — — High − ++ + −
BSS5 1 Gland comp. + C/M ++N — − ++ + −
Spindle comp. — — High − +/− + −
BSS6 2 Gland comp. + C/M ++N — +/− +/− +/− +/−
Spindle comp. — — High − ++ +/− +/−
BSS7 1 Gland comp. + C/M ++N — +/− ++ +/− +/−
Spindle comp. — — High − ++ +/− +/−
BSS8 2 Gland comp. + C/M ++N — − ++ +/− −
Spindle comp. — — High − ++ +/− −
BSS9 2 NV NV NV NV NV NV NV NV
− indicates no immunoreactivity; +/−, mild immunoreactivity; +, moderate immunoreactivity; ++, strong immunoreactivity; BSS, biphasic synovial sarcoma; C , cytoplasmatic staining; Gland comp.,
glandular component; M , membrane staining; MSS, monophasic synovial sarcoma; N , nuclear staining; NV, not valuable; Spindle comp., spindle component.
Translational Oncology Vol. 1, No. 2, 2008 RTK Signalling in Pediatric Synovial Sarcoma Bozzi et al. 97
manufacturer’s instructions. The relative changes in gene expression
were calculated using the 2−ΔΔC t method [13].
APC and β-Catenin Mutations
DNA was extracted from selected paraffin-embedded sections of
six MSS showing nuclear β-catenin, and β-catenin exon 3 was am-
plified as previously described [14]. No activating mutations were
found in these samples.
Results
Immunohistochemistry
Immunostaining was successful in all but case BSS9. The results are
shown in Table 2 and Figures 1 and 2 (MSS3 and BSS4, respectively).
Receptor tyrosine kinases: EGFR, PDGFRα, PDGFRβ, KIT, and
HER2/NEU. Epidermal growth factor receptor immunoreactivity
was high [9] in the cytoplasm of almost all of the tumor cells in five
of eight MSS but was restricted to the spindle cell component in all
of the BSS samples. Her2/Neu was negative in all of the MSS but
showed mild cytoplasmic reactivity in the glandular component of
three of nine BSS. Platelet-derived growth factor receptor α was reac-
tive in the cytoplasm of most of the MSS tumor cells and in the spin-
dle and glandular cells of the BSS; the same was true of PDGFRβ,
but the intensity of the staining was less in half the cases.
There was no Kit decoration in any of the MSS, and it was re-
stricted to the cytoplasm of the glandular component in five of nine
BSS, as previous reported [15].
β-Catenin and cyclin D1 products (bcl1). Because cyclin D1 can
be considered a marker of β-catenin activation, we evaluated the im-
munoreactivitiy of both proteins.
Most tumor cells in six of eightMSS cases showed nuclear or nuclear/
cytoplasmic β-catenin immunoreactivity, whereas cytoplasmic and cell
membrane immunostaining was restricted to the glandular compo-
nent in all of the BSS.
Nuclear bcl1 immunoreactivity was observed in 50% to 80% of
the MSS tumor cells and decorated all of the nuclei of the glandular
component in the BSS.
Figure 1. H/E section (A) of MSS3 (Table 1) showing β-catenin (B) and bcl1 (C) nuclear immunostaining, EGFR cytoplasmic membrane
overexpression (D), and PDGFRα cytoplasmic decoration (E).
Figure 2. Hematoxylin and eosin–stained section (A) of BSS4 (Table 1) showing β-catenin expression and bcl1 restricted to the glandular
component (B and C); β-catenin has a cytoplasmic membrane staining pattern (B) and bcl1 decorates the nuclei (C). Conversely, EGFR
expression highlights the spindle cell tumor component (D). Platelet-derived growth factor receptor α cytoplasmic immunostaining is
shared by both the epithelial and the spindle cell component (E).
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Relative Quantification of PDGFRα, PDGFRβ, and EGFR
mRNA Expression
Using a pool of normal mesenchymal-derived tissues as calibrators,
we observed an increase in the transcripts of EGFR (median, 1.7 ×
101; range, 1 × 100 to 1.9 × 102) and PDGFRα (median, 5 × 100;
range, 1 × 100 to 6.4 × 101); the median level of the PDGFRβ tran-
script was similar to that of the calibrator (median, 1 × 100; range,
1 × 10−1 to 4 × 100). These results support the high IHC EGFR and
PDGFRα scores in both the MSS and BSS.
Detection of EGFR and PDGFRα Ligands
Real-time PCR revealed the presence of the cognate ligand of
PDGFRα (PDGF-AA) and EGFR (TGFA) in all cases. Given the lack
of appropriate calibrators for the relative quantification of PDGF-AA
and TGFA, we compared their median C t values (26.5; range, 21.9–
29.7 for PDGF-AA; and 31.2; range, 27.3–34.8 for TGFA) with that
of the Gapdh housekeeping gene (25.9; range, 21.1–29).
Receptor Tyrosine Kinase Biochemical Analysis: EGFR,
PDGFRα, and PDGFRβ Expression and Phosphorylation
Because the IHC results suggested that the RTKs expressed in
most of the SS samples were EGFR, PDGFRα and, to a lesser extent,
PDGFRβ, we investigated their activation in immunoprecipitation
(IP)/WB analysis experiments.
Frozen samples of four MSS (#3, #4, #5, and #8) and three BSS
(#1, #4, and #8) were available for biochemical analysis (frozen
sections from both BSS1 and BSS4 had revealed an extensive glan-
dular component on histologic examination). After specific IP (with
anti-EGFR, anti-PDGFRα, and anti-PDGFRβ) and WB, all of the
samples expressed activated (i.e., phosphorylated) EGFR (Figure 3A
and Table 3), PDGFRα (Figure 3B and Table 3), and PDGFRβ
(not shown).
AKT Phosphorylation
To confirm RTK activation further, we investigated the presence
and activation of the shared downstream effector Akt, the phosphor-
ylation of which was evaluated directly by means of WB. This ex-
periment revealed phosphorylated Akt in six of seven SS samples
(Figure 3C and Table 3).
Specific Inhibition of PI3K Abolishes PDGF-AA–Induced Akt
Phosphorylation in the CME-1 SS Cell Line
Time-course studies of Akt activation (in the form of the phosphor-
ylation of Akt Ser 473 in response to PDGF-AA stimulation) showed
Akt activation in serum-starved CME-1 cells as early as 5 minutes after
stimulation with 50 ng/ml PDGF-AA; this peaked after 15 minutes
and returned to baseline values after 1 hour (not shown).
We next examined the effects of the established PI3K inhibitor
LY294002 on Akt activation in serum-starved and LY294002-treated
Figure 3. EGFR, PDGFRα, and Akt expression and activation in pe-
diatric SS. (A) EGFR expression and activation. Ctr+ indicates the
A431 cell line used as a positive control; M , marker; Pool, protein
pool derived from healthy mesodermal tissues; MSS3, MSS4,
MSS5, BSS1, and BSS4, proteins extracted from frozen SS sam-
ples. The receptor was represented by two bands (depending on
its glycosylation status) and is indicated by two arrows. (B)
PDGFRα expression and activation. Ctr+ indicates the NIH3T3 cell
line used as a positive control; M , marker; MSS3, MSS4, MSS5,
BSS1, and BSS4, proteins extracted from frozen SS samples. The
receptor is indicated by two arrows. (C) Akt expression and activa-
tion. Ctr1+ indicates the NIH3T3 cell line treated with PDGF as a
positive control for Akt phosphorylation; Ctr2+, untreated NIH3T3;
M , marker (93.6 and 106.9 kDa); MSS3, MSS4, MSS5, BSS1, and
BSS4, proteins extracted from frozen SS samples. The arrow indi-
cates that the pAKT is the lower band.
Table 3. Results of Biochemical Analysis of Frozen SS Samples.
Akt β-Catenin EGFR PDGFRα PDGFRβ
Protein pSer473 Protein pTyr142 Protein Phospo. Protein Phospo. Protein Phospo.
MSS3 +/− − + + + + + + + +
MSS4 + + Nd Nd + + + + + +
MSS5 + + − − + + + + + +
MSS8 + + + + + + + + + +
BSS1 + + + + + + + + + +
BSS4 + + + + + + + + + +
BSS8 + + + − + + + + + +
BSS indicates biphasic synovial sarcoma;MSS, monophasic synovial sarcoma; Nd, not done; phospho., phosphorylation detected by anti–pTYR after specific IP; pSer473, phosphorylation status of Ser 473
detected directly by WB; pTyr142, phosphorylation status Tyr 142 detected directly by WB.
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CME-1 cells and observed that Akt Ser 473 phosphorylation was com-
pletely abolished by the addition of 50 μg/ml LY294002 (Figure 4).
Receptor Tyrosine Kinase FISH Analysis
Because gene amplification is one of the mechanisms responsible
for RTK activation, we investigated EGFR, PDGFRα, and PDGFRβ
gene copy numbers by means of FISH in two MSS (#1 and #6) and
three BSS (#3, #5, and #7), all of which showed a normal disomic
hybridization pattern for all RTK receptors, which is consistent with
the absence of gene amplification.
Receptor Tyrosine Kinases and β-Catenin
As a further step, we extracted cytoplasmic β-catenin and assessed
its phosphorylation in tyrosine 142 (Y142). Western blot analysis
showed that all of the tested BSS samples (BSS1, BSS4, and BSS8)
had cytoplasmic β-catenin (thus confirming the IHC results), and
β-catenin Y142 phosphorylation was observed in BSS1 and BSS4
(Figure 5 and Table 3). Despite the definite prevalence of nuclear β-
catenin as IHC decoration in our MSS samples, Y142-phosphorylated
cytoplasmic β-catenin was also observed by WB in MSS3 and MSS8
(Figure 5 and Table 3), thus suggesting that IHC is not sensitive enough
to indicate β-catenin localization precisely.
In light of the above data, it can be assumed that the cytoplasmic
localization of β-catenin very often parallels its phosphorylation in
Y142. Because β-catenin Y142 phosphorylation can be achieved by
means of the formation of β-catenin/RTK complexes or the activation
of RTKs, and our IHC and IP/WB results suggested EGFR and
PDGFRα activation, the filters obtained after IP/WB analysis with
anti-EGFR and anti-PDGFRα were stripped and incubated with the
anti–β-catenin antibody. No β-catenin/EGFR or β-catenin/PDGFRα
coimmunoprecipitation was observed in either the MSS or the BSS
specimens (not shown).
Discussion
The most relevant finding of this comprehensive investigation of a
small, single-center series of pediatric SS cases is the presence of ac-
tivated (i.e., phosphorylated) EGFR, PDGFRα, and Akt, which was
supported by the biochemical results on snap-frozen material; we
have previously reported the activation of PDGFRβ in a series of cryo-
preserved SS specimens taken from adults [11]. It is also worth noting
the IHC evidence of nuclear β-catenin expression coupled with a cy-
clin D1 product (bcl1) in paraffin-embedded tissue; as previously re-
ported [16,17], these results confirm that cyclin D1 can be considered
one of the targets of activated β-catenin in SS.
Our biochemical data relating to cryopreserved samples and IHC
data relating to formalin-fixed material (all showing overexpressed
and activated EGFR, PDGFRα, and PDGFRβ), together with the
demonstration of each receptor’s cognate ligand by real-time PCR,
support the idea that Akt is activated in response to multiple signals
acting through the receptors through an autocrine/paracrine–mediated
loop. This was confirmed by the absence of the activating mutation
in EGFR [18] or PDGFRα [19] and the fact that the FISH data
ruled out any gene alteration in the involved RTKs. In line with these
findings, the Akt activation induced by PDGF-AA in the CME-1 SS
cell line was completely abolished by the specific PI3K inhibitor
LY294002, thus confirming that the PI3K/Akt pathway is biolog-
ically active in SS cell lines and is a potential therapeutic target in
SS patients.
We also found a nuclear β-catenin expression in MSS and the in-
creased expression of cyclin D1 (a β-catenin target gene) in both
MSS and BSS. These findings not only indicate that this gene is acti-
vated but also suggest a possible mechanism underlying the β-catenin
activation. The absence of β-catenin gene mutations in the six MSS
showing nuclear β-catenin immunoreactivity and the absence of
RTK/β-catenin complexes at IP analysis rule out the possibility that
either are responsible for the nuclear localization of β-catenin; how-
ever, because our model highlighted the presence of activated Akt (a
serine/threonine kinase downstream target of EGFR, PDGFRα, and
PDGFRβ), this could presumably assist the nuclear translocation of
β-catenin through its serine 552 phosphorylation or the direct inhi-
bition of GSK3B [3]. Unfortunately, the lack of protein extract from
Figure 4. Akt activation and inhibition in the CME-1 SS cell line. The
NIH3T3 cell line (lane 1) was used as a positive control. The cell
showed low Akt phosphorylation after starvation (lane 2), but
a high degree of activation when it was stimulated with 50 ng/ml
of PDGF-AA for 15 minutes (lane 3). Akt Ser 473 phosphorylation
was progressively reduced when the LY294002 PI3K inhibitor was
added at 0.5, 5, and 50 μM (lanes 4, 5, and 6).
Figure 5. β-Catenin expression and activation. Ctr+ indicates the A431 cell line used as a positive control; Ctr+b, bacterial recombinant
β-catenin; M , marker; MSS3, MSS5, BSS1, and BSS4, proteins extracted from frozen SS samples.
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our frozen material prevented us from analyzing whether all these
cases were also phosphorylated on serine residues.
The detection of cytoplasmic β-catenin Y142 phosphorylation
coupled with a cytoplasmic decoration indicates that this residue
may be important for the cytoplasmic localization. This is an intrigu-
ing point because, as previously observed in BSS [20], we found that
β-catenin expression was restricted to the BSS glandular component,
thus indicating a shift from the nucleus to the cytoplasm and/or cy-
toplasm membrane. In this light, the detection of β-catenin phos-
phorylation on a Tyr 142 residue in two of our BSS supports the
possibility that the change in the localization of β-catenin occurs dur-
ing the mesenchymal–epithelial transition, particularly because there
was no correlation between the transcript type and the type of resi-
due activation.
A clinical trial of geftinib (an EGFR inhibitor) in SS patients with
locally advanced or metastatic disease has been conducted in Europe
[21], despite the rare occurrence of EGFR mutations [18] and the
gain in gene copy number (confirmed by our results). Inhibiting a
downstream effector (such as Akt) to block multiple upstream acti-
vated RTKs (EGFR, PDGFRα, and PDGFRβ) seems to be a further
promising therapeutic possibility as we found that more than one
receptor is activated at the same time and direct Akt inhibitors have
recently been developed.
It is also worth noting that a previous IHC-based study of non–
small cell lung carcinoma [22] found that patients whose surgical
specimens showed high levels of both EGFR and Akt activation were
more sensitive to RTK inhibitors. Although the results of this study
must be considered with caution as the antibody has now been with-
drawn from production, the clinical evidence of a response seems to
be reliable. We are faced with the problem of the reliability of IHC
phospho-specific antibodies every day and find that they do not as-
sure reproducible results, which is why they were not used in the
present study.
Our comprehensive investigation of a small, single-center series of
SS in children and adolescents adds molecular details to the scanty
published findings concerning the biology of pediatric SS. They may
also be of interest to clinicians as it is still debated whether SS has the
same clinical behavior (and the same biology) in different age groups
[23]. This is important because SS are not always treated using the
same strategy in different ages, and there is still disagreement be-
tween pediatric and adult medical oncologists concerning the role
of chemotherapy.
In conclusion, although very preliminary and needing confirmation
in a larger series, our finding that multireceptor-mediated Akt activa-
tion (and its inhibition by a PI3K inhibitor in the CME-1 SS cell line)
may stabilize β-catenin in SS strongly suggests that inhibiting the
PI3K/Akt pathway may be a useful adjunctive therapeutic strategy.
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